Solid Biosciences Receives European Orphan Drug Designation for SGT-003 Duchenne Muscular Dystrophy Treatment

Key Takeaways

• European Commission grants orphan drug designation to Solid Biosciences’ SGT-003 for Duchenne muscular dystrophy treatment
• Designation provides regulatory incentives including market exclusivity and reduced fees to support rare disease drug development
• Move strengthens Solid’s global development strategy for precision genetic medicine targeting neuromuscular disorders

---

Solid Biosciences Inc. (Nasdaq: SLDB) announced April 28, 2026, that the European Commission has granted orphan drug designation for SGT-003, the company’s investigational gene therapy for Duchenne muscular dystrophy (DMD).

The Charlestown, Massachusetts-based life sciences company develops precision genetic medicines for neuromuscular and cardiac diseases. This European regulatory milestone follows the company’s commitment to advancing SGT-003 through global clinical development for individuals living with DMD.

What Orphan Drug Designation Means

Orphan drug designation is granted to treatments for rare diseases affecting fewer than 5 in 10,000 people in the European Union. The status provides significant regulatory and commercial incentives, including:

• Up to 10 years of market exclusivity upon approval
• Reduced regulatory fees
• Scientific advice and protocol assistance from European Medicines Agency (EMA)
• Access to centralized marketing authorization procedure

Market Impact and Development Timeline

Duchenne muscular dystrophy affects approximately 1 in 3,500 to 5,000 male births worldwide, making it the most common fatal genetic disorder diagnosed in childhood. The progressive muscle-wasting disease typically leads to wheelchair dependence by adolescence and life-threatening complications in early adulthood.

Solid Biosciences’ SGT-003 represents a next-generation gene therapy approach designed to address limitations of current DMD treatments. The European designation complements the company’s regulatory strategy across multiple jurisdictions, potentially accelerating patient access to innovative genetic medicine.

Industry Context

The orphan drug market continues expanding as biotechnology companies focus on rare disease treatments with significant unmet medical needs. European regulatory support through orphan designation helps offset high development costs associated with genetic therapies while encouraging innovation in precision medicine.

This milestone positions Solid Biosciences to advance SGT-003 development with enhanced regulatory pathway clarity and commercial protection in the European market, supporting the company’s broader neuromuscular disease portfolio strategy.

---

Frequently Asked Questions

What does orphan drug designation mean for DMD patients?

Orphan drug designation accelerates SGT-003 development by providing regulatory incentives and streamlined approval pathways, potentially bringing this gene therapy to European DMD patients faster than traditional development routes.

When will SGT-003 be available to patients?

SGT-003 is still in development and must complete clinical trials and receive marketing authorization before becoming available. The orphan designation supports this process but specific timelines depend on ongoing study results and regulatory review.

How does SGT-003 compare to existing DMD treatments?

SGT-003 is a gene therapy designed to address underlying genetic causes of DMD, potentially offering more comprehensive treatment than current approaches that primarily manage symptoms or slow disease progression.